RS55566B1 - Farmaceutska kompozicija - Google Patents
Farmaceutska kompozicijaInfo
- Publication number
- RS55566B1 RS55566B1 RS20170008A RSP20170008A RS55566B1 RS 55566 B1 RS55566 B1 RS 55566B1 RS 20170008 A RS20170008 A RS 20170008A RS P20170008 A RSP20170008 A RS P20170008A RS 55566 B1 RS55566 B1 RS 55566B1
- Authority
- RS
- Serbia
- Prior art keywords
- pharmaceutical composition
- pharmaceutical
- composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
- C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D231/18—One oxygen or sulfur atom
- C07D231/20—One oxygen atom attached in position 3 or 5
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38478110P | 2010-09-21 | 2010-09-21 | |
| PCT/US2011/051163 WO2012039972A1 (en) | 2010-09-21 | 2011-09-12 | Pharmaceutical composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS55566B1 true RS55566B1 (sr) | 2017-05-31 |
Family
ID=44674894
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20170008A RS55566B1 (sr) | 2010-09-21 | 2011-09-12 | Farmaceutska kompozicija |
Country Status (30)
| Country | Link |
|---|---|
| US (2) | US8686018B2 (sr) |
| EP (2) | EP3061751A1 (sr) |
| JP (1) | JP5956448B2 (sr) |
| KR (1) | KR101911105B1 (sr) |
| CN (1) | CN103097358B (sr) |
| AU (1) | AU2011305872B2 (sr) |
| BR (1) | BR112013002484B1 (sr) |
| CA (1) | CA2806121C (sr) |
| CL (1) | CL2013000675A1 (sr) |
| CY (1) | CY1118680T1 (sr) |
| DK (1) | DK2619182T3 (sr) |
| ES (1) | ES2610185T3 (sr) |
| HR (1) | HRP20170042T1 (sr) |
| HU (1) | HUE031408T2 (sr) |
| IL (1) | IL224288A (sr) |
| LT (1) | LT2619182T (sr) |
| ME (1) | ME02575B (sr) |
| MX (1) | MX2013003162A (sr) |
| MY (1) | MY162146A (sr) |
| NZ (1) | NZ606629A (sr) |
| PE (1) | PE20131343A1 (sr) |
| PL (1) | PL2619182T3 (sr) |
| PT (1) | PT2619182T (sr) |
| RS (1) | RS55566B1 (sr) |
| RU (1) | RU2606510C2 (sr) |
| SG (1) | SG188188A1 (sr) |
| SI (1) | SI2619182T1 (sr) |
| SM (1) | SMT201700008B (sr) |
| UA (1) | UA113499C2 (sr) |
| WO (1) | WO2012039972A1 (sr) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR091429A1 (es) * | 2012-06-29 | 2015-02-04 | Lilly Co Eli | Compuestos de fenoxietil piperidina |
| MY168609A (en) | 2013-06-12 | 2018-11-14 | Kaken Pharma Co Ltd | 4-alkynyl imidazole derivative and medicine comprising same as active ingredient |
| TW201623277A (zh) * | 2014-03-26 | 2016-07-01 | 安斯泰來製藥股份有限公司 | 醯胺化合物 |
| CN106572993B (zh) * | 2014-05-23 | 2019-07-16 | 卫材R&D管理有限公司 | Ep4拮抗剂在制备治疗癌症的药物中的应用 |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| DK3325490T3 (da) | 2015-07-23 | 2020-02-03 | Takeda Pharmaceuticals Co | 1-substituerede 1,2,3,4-tetrahydro-1,7-naphthyridin-8-aminderivater og deres anvendelse som ep4-receptorantagonister |
| BR112018007664B1 (pt) | 2015-10-16 | 2023-12-19 | Eisai R&D Management Co., Ltd | Compostos antagonistas de ep4, composição compreendendo o composto e uso dos mesmos para tratar câncer |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| US11839613B2 (en) | 2017-05-18 | 2023-12-12 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| EP3625224B1 (en) | 2017-05-18 | 2021-08-04 | Idorsia Pharmaceuticals Ltd | N-substituted indole derivatives |
| KR102612649B1 (ko) | 2017-05-18 | 2023-12-11 | 이도르시아 파마슈티컬스 리미티드 | Pge2 수용체 조절제로서의 벤조푸란 및 벤조티오페논 유도체 |
| CA3063788A1 (en) | 2017-05-18 | 2018-11-22 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives |
| AU2018269666B2 (en) | 2017-05-18 | 2022-02-03 | Idorsia Pharmaceuticals Ltd | Phenyl derivatives as PGE2 receptor modulators |
| CN108929281B (zh) * | 2017-05-27 | 2021-12-24 | 华东师范大学 | 三氮唑类化合物及其合成方法和应用 |
| AU2019214193B2 (en) * | 2018-02-05 | 2022-06-16 | Foshan Ionova Biotherapeutics Co., Inc. | Heterobicyclic carboxylic acids for treating cancer or inflammatory diseases |
| CA3170288A1 (en) * | 2020-03-04 | 2021-09-10 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Synthesis of novel ep4 antagonist and use in cancer and inflammation |
| CN114075140A (zh) * | 2020-08-18 | 2022-02-22 | 武汉人福创新药物研发中心有限公司 | 作为ep4受体拮抗剂的吡唑酰胺衍生物及其在癌症和炎症中的用途 |
| KR20230107228A (ko) | 2020-11-13 | 2023-07-14 | 오노 야꾸힝 고교 가부시키가이샤 | Ep4 길항약과 면역 체크포인트 저해 물질의 병용에 의한 암 치료 |
| TW202227089A (zh) | 2020-11-30 | 2022-07-16 | 大陸商杭州阿諾生物醫藥科技有限公司 | 用於治療ｐｉｋ３ｃａ突變癌症的組合療法 |
| EP4286371A1 (en) * | 2021-01-28 | 2023-12-06 | Shenzhen Zhongge Biological Technology Co., Ltd. | Pyrazolamide derivative, preparation method therefor, and application thereof |
| TW202328073A (zh) * | 2021-09-03 | 2023-07-16 | 大陸商武漢人福創新藥物研發中心有限公司 | Ｅｐ４拮抗劑化合物及其鹽、多晶型及其製備方法和用途 |
| CN115364222A (zh) * | 2021-09-09 | 2022-11-22 | 首都医科大学附属北京地坛医院 | Ep4受体抑制剂治疗肝纤维化的应用 |
| KR20240124927A (ko) | 2021-12-23 | 2024-08-19 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | Ep4 길항제의 결정질 염 형태 |
| WO2023125724A1 (zh) * | 2021-12-30 | 2023-07-06 | 杭州阿诺生物医药科技有限公司 | 一种固体药物组合物 |
| WO2024027599A1 (zh) * | 2022-08-04 | 2024-02-08 | 杭州阿诺生物医药科技有限公司 | 预测直肠癌对an0025联合放疗/放化疗(rt/crt)治疗敏感性的生物标志物 |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH0421671A (ja) * | 1990-05-16 | 1992-01-24 | Mitsubishi Kasei Corp | ４―ピラゾールカルボキサミド類およびこれを有効成分とする殺虫、殺ダニ剤 |
| IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
| US6211197B1 (en) * | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US7119108B1 (en) | 1999-10-18 | 2006-10-10 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
| US7393842B2 (en) | 2001-08-31 | 2008-07-01 | University Of Connecticut | Pyrazole analogs acting on cannabinoid receptors |
| HN2001000224A (es) | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
| TW591020B (en) | 2001-06-20 | 2004-06-11 | Wyeth Corp | 6-(aryl-amido or aryl-amidomethyl)-naphthalen-2-yloxy-acidic derivatives as inhibitors of plasminogen activator inhibitor type-1 (PAI-1) |
| US20050113283A1 (en) | 2002-01-18 | 2005-05-26 | David Solow-Cordero | Methods of treating conditions associated with an EDG-4 receptor |
| AU2003285012A1 (en) | 2002-10-24 | 2004-05-13 | Sepracor, Inc. | Compositions comprising zopiclone derivatives and methods of making and using the same |
| FR2847160A1 (fr) | 2002-11-20 | 2004-05-21 | Oreal | Composition capillaire contenant un compose pyrasol-carboxamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute |
| GB0302094D0 (en) | 2003-01-29 | 2003-02-26 | Pharmagene Lab Ltd | EP4 receptor antagonists |
| ATE517872T1 (de) * | 2003-06-26 | 2011-08-15 | Novartis Ag | Fünfgliedrige p38-kinaseinhibitoren auf heterocyclusbasis |
| EA009201B1 (ru) | 2003-09-03 | 2007-12-28 | Пфайзер Инк. | Фенил - или пиридиламидные соединения в качестве антагонистов простагландина e2 |
| GT200500013A (es) | 2004-01-23 | 2005-08-10 | Amidas herbicidas | |
| CA2565660C (en) * | 2004-05-04 | 2009-11-03 | Pfizer Inc. | Ortho substituted aryl or heteroaryl amide compounds |
| CA2565813C (en) * | 2004-05-04 | 2010-10-26 | Pfizer Inc. | Substituted methyl aryl or heteroaryl amide compounds |
| EP1894919B1 (en) | 2005-06-07 | 2012-03-28 | Shionogi & Co., Ltd. | Heterocyclic compound having type i 11 beta hydroxysteroid dehydrogenase inhibitory activity |
| WO2006134318A1 (en) * | 2005-06-11 | 2006-12-21 | Vernalis R & D Limited | Pyrazole-substituted benzimidazole derivatives for use in the treatment of cancer and autoimmune disorders |
| CN101273013B (zh) * | 2005-09-27 | 2013-06-12 | 盐野义制药株式会社 | 具有pgd2受体拮抗活性的磺酰胺衍生物 |
| CN102659659B (zh) | 2005-11-21 | 2014-07-23 | 盐野义制药株式会社 | 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物 |
| EP1988081B1 (en) * | 2006-02-06 | 2012-10-17 | Taisho Pharmaceutical Co., Ltd | Binding inhibitor of sphingosine-1-phosphate |
| JP5183628B2 (ja) | 2006-06-12 | 2013-04-17 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのインドリンアミド誘導体 |
| JP5259592B2 (ja) | 2006-08-11 | 2013-08-07 | メルク カナダ インコーポレイテッド | Ｅｐ４受容体リガンドとしてのチオフェンカルボキサミド誘導体 |
| NZ577109A (en) | 2006-12-15 | 2011-12-22 | Glaxo Group Ltd | Benzamide derivatives as ep4 receptor agonists |
| ES2400293T3 (es) | 2007-02-26 | 2013-04-08 | Merck Canada Inc. | Derivados de indol e indolina ciclopropilamida como antagonistas de receptores EP4 |
| US7560936B1 (en) | 2007-04-24 | 2009-07-14 | Integrated Device Technology, Inc. | Method and apparatus for ground bounce and power supply bounce detection |
| ATE520667T1 (de) | 2007-06-15 | 2011-09-15 | Basf Se | Verfahren zur herstellung difluormethylsubstituierter pyrazolverbindungen |
| US20110028463A1 (en) | 2007-07-03 | 2011-02-03 | Astellas Pharma Inc. | Amide compounds |
| PT2178865E (pt) * | 2007-07-19 | 2015-11-16 | Lundbeck & Co As H | Amidas heterocíclicas com 5 membros e compostos relacionados |
| AR067744A1 (es) | 2007-07-31 | 2009-10-21 | Bayer Cropscience Sa | Derivados fungicidas de (hetero) aril- metilen -n- cicloalquil carboxamida condensados de 6 elementos con n |
| GB0721611D0 (en) | 2007-11-02 | 2007-12-12 | Glaxo Group Ltd | Novel compounds |
| CA2722811C (en) * | 2008-05-06 | 2016-07-05 | Boehringer Ingelheim International Gmbh | Pyrazole compounds as ccr1 antagonists |
| ES2518919T3 (es) | 2008-05-14 | 2014-11-05 | Astellas Pharma Inc. | Derivados del ácido 4-(Indol-7-ilcarbonilaminometil)ciclohexanocarboxílico como antagonistas del receptor EP4 útiles para el tratamiento de la insuficiencia renal crónica o la nefropatía diabética |
| CN102123985B (zh) | 2008-08-01 | 2014-05-28 | 拜尔农科股份公司 | 杀真菌剂n-环烷基-n-联苯甲基-羧酰胺衍生物 |
| CA2733247C (en) * | 2008-08-14 | 2018-04-03 | Beta Pharma Canada Inc. | Heterocyclic amide derivatives as ep4 receptor antagonists |
| CN102224154A (zh) | 2008-09-25 | 2011-10-19 | 默克弗罗斯特加拿大有限公司 | 作为EP4受体拮抗剂的β-咔啉磺酰脲衍生物 |
-
2011
- 2011-09-12 CN CN201180045222.XA patent/CN103097358B/zh active Active
- 2011-09-12 MX MX2013003162A patent/MX2013003162A/es active IP Right Grant
- 2011-09-12 NZ NZ60662911A patent/NZ606629A/en unknown
- 2011-09-12 WO PCT/US2011/051163 patent/WO2012039972A1/en active Application Filing
- 2011-09-12 RS RS20170008A patent/RS55566B1/sr unknown
- 2011-09-12 RU RU2013118209A patent/RU2606510C2/ru active
- 2011-09-12 MY MYPI2013700146A patent/MY162146A/en unknown
- 2011-09-12 PL PL11760631T patent/PL2619182T3/pl unknown
- 2011-09-12 KR KR1020137004494A patent/KR101911105B1/ko active IP Right Grant
- 2011-09-12 SI SI201131067A patent/SI2619182T1/sl unknown
- 2011-09-12 CA CA2806121A patent/CA2806121C/en active Active
- 2011-09-12 ES ES11760631.9T patent/ES2610185T3/es active Active
- 2011-09-12 EP EP16161460.7A patent/EP3061751A1/en not_active Withdrawn
- 2011-09-12 PE PE2013000320A patent/PE20131343A1/es active IP Right Grant
- 2011-09-12 BR BR112013002484-4A patent/BR112013002484B1/pt active IP Right Grant
- 2011-09-12 PT PT117606319T patent/PT2619182T/pt unknown
- 2011-09-12 AU AU2011305872A patent/AU2011305872B2/en active Active
- 2011-09-12 SG SG2013007174A patent/SG188188A1/en unknown
- 2011-09-12 LT LTEP11760631.9T patent/LT2619182T/lt unknown
- 2011-09-12 EP EP11760631.9A patent/EP2619182B1/en active Active
- 2011-09-12 ME MEP-2017-3A patent/ME02575B/me unknown
- 2011-09-12 UA UAA201304961A patent/UA113499C2/uk unknown
- 2011-09-12 HU HUE11760631A patent/HUE031408T2/en unknown
- 2011-09-12 JP JP2013530177A patent/JP5956448B2/ja active Active
- 2011-09-12 DK DK11760631.9T patent/DK2619182T3/en active
-
2013
- 2013-01-17 IL IL224288A patent/IL224288A/en active IP Right Grant
- 2013-03-12 CL CL2013000675A patent/CL2013000675A1/es unknown
- 2013-03-12 US US13/795,768 patent/US8686018B2/en active Active
-
2014
- 2014-02-05 US US14/173,170 patent/US9000024B2/en active Active
-
2017
- 2017-01-09 SM SM201700008T patent/SMT201700008B/it unknown
- 2017-01-11 HR HRP20170042TT patent/HRP20170042T1/hr unknown
- 2017-01-19 CY CY20171100079T patent/CY1118680T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1246170A1 (zh) | 藥物組合物 | |
| IL225457A0 (en) | Pharmaceutical composition | |
| PT2619182T (pt) | Composição farmacêutica | |
| EP2616076A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| ZA201304189B (en) | Novel pharmaceutical composition | |
| PT2579858E (pt) | Composição farmacêutica que contém ivabradina | |
| ZA201301920B (en) | Pharmaceutical composition | |
| GB201010453D0 (en) | Pharmaceutical composition | |
| EP2635307A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| IL221501A (en) | Medicinal product containing miramistine | |
| GB201001911D0 (en) | Pharmaceutical composition | |
| EP2560678A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB201019775D0 (en) | Pharmaceutical composition | |
| HU1000006D0 (en) | Improved pharmaceutical composition | |
| EP2642996A4 (en) | PHARMACEUTICAL COMPOSITIONS | |
| GB201008590D0 (en) | Pharmaceutical compositions |